Τόμος 15 (1997) – Τεύχος 3 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 15 (1997) – Issue 3 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Βασίλης Κόκκας

Ερ­γα­στή­ριο Φαρ­μα­κο­λο­γί­ας, Ια­τρι­κή Σχο­λή, Α­ρι­στο­τέ­λει­ο Πα­νε­πι­στή­μιο, Θεσ­σα­λο­νί­κη, Ελ­λάς

Basilis Kokkas

Laboratory of Pharmacology, School of Medicine, Aristotle University, Thessaloniki, Greece

2. Belpaire F.: Drug metabolism. Pharmed Seminar-ULB, Brussels, 1997

3. Omeun G.: Predictive identification of hypersucceptible individuals. J. Occup. Med. 24: 369-374 (1982)

4. Berlo J.: Drug metabolism. Pharmed Seminar-ULB, Brus­sels, 1997

5. Παραδέλλης Α.: Φαρμακολογία. University Studio Press, Θεσσαλονίκη, 1992

6. Correia M.: Drug metabolism. In: (Katzung B., ed.) Basic and clinical pharmacology. P. 48, Prentice Hall Intern. Inc., Con. USA, 1995

7. Bennet L., Kroetz D., Sheiner.: Pharmacokinetics In: (Hardman J. et al., eds). Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 3-27, McGraw Hill, New York, 1996

8. Gumncio J., Chianale J.: Liver cell heterogenity and liver function. In: (Arias I. et al., eds) The Liver: Biology and Pa­thology. P. 93, Raven Press, New York, 1988

9. Forrester I., Wolf C.: Genetic susceptibility to environmental insults. In: (Conen R. et al. eds). P. 3, The Metabolic and Molecular Basis of Acquired Disease. P. 3, Bailliere Tindall, London, 1988

10. Knodel R., Hall S., Wilkinson G., Guengerich F.: In vitro evidence that tolbutamide hydroxylated by some human cy­tochrome P-450 form responsible for mephenytoin 4-hy­droxylation. Fed. Proc. 45: 320-324 (1986)

11. Maehan R., Gosden J., Rout D.: Human cytochrome P-450 PB-1: a multiple family involved in mephenytoin and steroid oxidations which maps to chromosome 10. Am. J. Hum. Genet. 42: 26-37 (1988)

12. Anderson T., Cederberg C., Edvardsonn G., Heggelund A., Lundborg P.: Effect of omeprazole treatment on diaze­pam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47: 79-85 (1990)

13. Ayesh R., Idle J., Ritchie J., Crothers M., Hetzel M.: Metabolic activation phenotypes as markers for susceptibility to long cancer. Nature 311: 169-170 (1985)

14. Gonzalez F., Schmid B., Umeno M., et al.: Human P450PCN1. Sequence, Chromosomal localization and direct evidence through. DNA expression that P450PCN1 is nifedipine oxidase. DNA 7: 79-86 (1988)

15. Spurr N., Cough A., Stevenson K., Woff C.: The human cytochrome P450CYP3 locus. Assignment to chromosome 7q22-qter. Annu. Hum. Gen. 81: 171-174 (1988)

16. Evans D., Eze L., Whitley E.: The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet. 20: 330-333 (1983)

17. Seidegard J., Pero R., Miller D., Boattie E.: A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7: 751-753 (1986)

18. Muller R.: Skeletal muscle relaxants. In: (Katzung B., ed.) Basic and clinical pharmacology. P. 404, Prentice Hall, Con. USA, 1995

19. Yoshida A., Motulsky A.: A pseudocholinesterase activity and succinylcholine resistance. A genetic variant. J. Clin. Invest. 45: 380-387 (1969)

20. Taylor P.: Anticholinesterase agents. In: (Hardman J. et al., eds) Goodman and Gilman’s. The pharmacological basis of therapeutics. Pp. 161-176, McGraw Hill, New York, 1996

21. Adkins S., Gank K., Mody M., Ladu B.: Molecular basis for the polymorphic forms of human serum paraoxonase / arylesterase glutamine or arginine at position 191 for re­spective A and B allozymes. Am. J. Hum. Genet. 52: 598-608 (1993)

22. Weinshilboum R.: Methyltransferase pharmacogenetics. Pharmacol. Ther. 43: 77-90 (1989)

23. Solomon H.: Variations in metabolism of coumarin anti­coagulant drugs. Ann. N.Y. Acad. Sci. 151: 932-935 (1968)

24. Smith M.: Genetics of human alcohol and aldehyde dehy­drogenases. Adv. Hum. Genet. 15: 249-290 (1986)

25. Lee N., Becker Ch.: The alcohols. In: (Katzung B., ed.) Basic and clinical pharmacology. P. 351, Prentice Hall, Con. USA, 1995

26. Παραδέλλης Α.: Αλληλεπιδράσεις φαρμάκων. Univer­sity Studio Press, Θεσσαλονίκη, 1990

27. Τρακατέλλης Α.: Βιοχημεία. Γραφικές Τέχνες Γ. Δεδουση, Θεσσαλονίκη, 1992

28. Stryer L.: Βιοχημεία. Σελ. 150-182, Πανεπιστημιακές Εκδόσεις Κρήτης, Ηράκλειο, 1994

29. Rodwell V.: Proteins: Myoglobin and Hemoglobin. In: (Murray R. et al. eds) Harper’s Biochemistry. Pp. 48-57, Prentice Hall, Con. USA, 1990

30. Muller C., Kingman S.: Hemoglobin Zurich. Biochim. Bio­phys. Acta 50: 595-598 (1961)

31. Guyton A., Hall J. (eds): Textbook of Medical Physiol­ogy. P. 855, Saunders W. Co., Philadelphia USA, 1996

32. Andreoli T., Carpenter C., Plum F., Smith L.: Cecil: Es­sentials of medicine. P. 343, Saunders W. Co., Philadel­phia USA, 1990

33. Otsu K., Nishida K., Kimura Y.: The point mutation Arg 15-cys in the Ca2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J. Biol. Chem. 269: 9413-9415 (1994)

34. MacLennan D., Phillips M.: Malignant hyperthermia. Sci­ence 257: 789-794 (1992)

35. Babe K., Serafin W.: Histamine, bradykinin and their an­tagonists. In: (Hardman J. et., eds) Goodman and Gilman’s. The pharmacological basis of therapeutics. Pp. 581-600, McGraw Hill, New York, 1996

36. Serafin W.: Drugs used in the treatment of asthma. In: (Hardman J. et al., eds) Goodman and Gilman’s. The phar­macological basis of therapeutics. Pp. 659-682, McGraw Hill, New York, 1996

37. Penno M., Vessel E.: Monogenic control of variations in antipyrine metabolic formation. New polymorphism of hepatic drug oxidation. J. Clin. Invest. 71: 1698-1709 (1983)

38. Jick H., Slone D., Westerholm B., Immain W., Vessey M., Shapiro S.: Venouw thromboembolic disease and ABO blood type. A cooperative study. Lancet: 539-542 (1969)

39. Smeraldi E., Bellodi L., Sacchetti E., Cazzullo C.: The HLA system and the clinical response to treatment with chlorpromazine. Br. J. Psychiatry 129: 486-489 (1976)

40. Perris C., Strandman E., Wahlby L.: HLA antigens and the response to prophylactic lithium. Neuropsychology 5: 114-118 (1979)

41. Wooley P., Griffin J., Panayi G., Batchelor J., Welsh K., Gibson T.: HLA-DR antigens and toxic reaction to sodium aurothiomalate and d-penicillamine in patients with rheuma­toid arthritis. N. Engl. J. Med. 303: 300-302 (1980)

42. Schmidt K., Mueller-Eckhardt C.: Agranulocytosis, le­vamisole and HLA-B27. Lancet 2: 85-88 (1977)

43. Batchelor J., Welsh K., Mansilla Tinoco R., Dollery C., Hughes G., Bernstein R.: Hydralazine induced systemic lupus erythematosus. Influence of HLA-DR and sex on susceptibility. Lancet 1: 1107-1109 (1980)